Education
About Us
Working with TipRanks
Follow Us
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
Total Valuation
Contineum Therapeutics, Inc. Class A has a market cap or net worth of $306.67M. The enterprise value is -$66.93M.
Market Cap$306.67M
Enterprise Value-$66.93M
Share Statistics
Contineum Therapeutics, Inc. Class A has 23,099,173 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,099,173
Owned by Insiders0.80%
Owned by Institutions45.58%
Financial Efficiency
Contineum Therapeutics, Inc. Class A’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -24.91%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-24.91%
Return on Capital Employed (ROCE)-0.25
Revenue Per Employee0.00
Profits Per Employee-1.03M
Employee Count41
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Contineum Therapeutics, Inc. Class A is ―. Contineum Therapeutics, Inc. Class A’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio1.43
Price to Fair Value1.43
Price to FCF-8.50
Price to Operating Cash Flow-5.97
PEG Ratio0.02
Income Statement
In the last 12 months, Contineum Therapeutics, Inc. Class A had revenue of 0.00 and earned -42.26M in profits. Earnings per share was -2.18.
Revenue0.00
Gross Profit-258.00K
Operating Income-50.89M
Pretax Income-42.26M
Net Income-42.26M
EBITDA-42.00M
Earnings Per Share (EPS)-2.18
Cash Flow
In the last 12 months, operating cash flow was -52.47M and capital expenditures -355.00K, giving a free cash flow of -52.83M billion.
Operating Cash Flow-52.47M
Free Cash Flow-52.83M
Free Cash Flow per Share-2.29
Dividends & Yields
Contineum Therapeutics, Inc. Class A pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change-28.78%
50-Day Moving Average11.38
200-Day Moving Average7.39
Relative Strength Index (RSI)47.44
Average Volume (3m)170.88K
Important Dates
Contineum Therapeutics, Inc. Class A upcoming earnings date is Mar 5, 2026, After Close (Confirmed).
Last Earnings DateOct 30, 2025
Next Earnings DateMar 5, 2026
Ex-Dividend Date―
Financial Position
Contineum Therapeutics, Inc. Class A as a current ratio of 20.69, with Debt / Equity ratio of 3.04%
Current Ratio20.69
Quick Ratio20.69
Debt to Market Cap0.02
Net Debt to EBITDA0.37
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Contineum Therapeutics, Inc. Class A has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Contineum Therapeutics, Inc. Class A EV to EBITDA ratio is -6.38, with an EV/FCF ratio of -8.03.
EV to Sales0.00
EV to EBITDA-6.38
EV to Free Cash Flow-8.03
EV to Operating Cash Flow-8.15
Balance Sheet
Contineum Therapeutics, Inc. Class A has $182.41M in cash and marketable securities with $5.49M in debt, giving a net cash position of $176.91M billion.
Cash & Marketable Securities$182.41M
Total Debt$5.49M
Net Cash$176.91M
Net Cash Per Share$7.66
Tangible Book Value Per Share$10.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Contineum Therapeutics, Inc. Class A is $21.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.25
Price Target Upside94.24% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast-100.71%